Factors Associated with Mortality in Immunocompetent Patients with Hospital-acquired Pneumonia

Pavaruch Sangmuang, Aroonrut Lucksiri, Wasan Katip, Pavaruch Sangmuang, Aroonrut Lucksiri, Wasan Katip

Abstract

Aim: The aim of the study is to determine the factors associated with 28-day mortality in immunocompetent patients with hospital-acquired pneumonia (HAP).

Methods: This was a 42-month retrospective cohort study in Chiang Kham Hospital. Patients with HAP diagnosed between January 2013 and June 2016 who did not have an immunocompromised status were recruited into the study.

Statistical analysis used: Univariable and multivariable binary logistic regression analyses were performed to determine the factors associated with mortality in patients with HAP.

Results: A total of 181 HAP patients. The most causative pathogens were nonfermenting Gram-negative bacilli. Fifty-two (28.7%) patients had died within 28 days after HAP diagnosis. Multivariable analysis demonstrated that mechanical ventilation (MV) dependency (adjusted odds ratio [OR] = 3.58, 95% confidence interval [CI] 1.53-8.37, P = 0.003), antibiotic duration (adjusted OR = 0.79, 95% CI 0.70-0.88, P < 0.001), acute kidney injury (adjusted OR = 5.93, 95% CI 1.29-27.22, P = 0.022), and hematologic diseases (adjusted OR = 11.45, 95% CI 1.61-81.50, P = 0.015) were the significant factors associated with 28-day mortality.

Conclusions: The factors associated with mortality were MV dependency, HAP duration of treatment, acute kidney injury, and hematologic disease. Early recognition of these factors in immunocompetent patients with HAP and treatment with intensive care may improve the outcome.

Keywords: Factors; hospital-acquired pneumonia; immunocompetent; mortality; multivariable model.

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
The ROC curve of multivariable model

References

    1. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63:e61–111.
    1. Sopena N, Sabrià M. Neunos 2000 Study Group. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest. 2005;127:213–9.
    1. Werarak P, Kiratisin P, Thamlikitkul V. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj hospital: Etiology, clinical outcomes, and impact of antimicrobial resistance. J Med Assoc Thai. 2010;93(Suppl 1):S126–38.
    1. Lee SC, Hua CC, Yu TJ, Shieh WB, See LC. Risk factors of mortality for nosocomial pneumonia: Importance of initial anti-microbial therapy. Int J Clin Pract. 2005;59:39–45.
    1. Micek ST, Heuring TJ, Hollands JM, Shah RA, Kollef MH. Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy. 2006;26:204–13.
    1. Micek ST, Chew B, Hampton N, Kollef MH. A case-control study assessing the impact of nonventilated hospital-acquired pneumonia on patient outcomes. Chest. 2016;150:1008–14.
    1. Siempos II, Vardakas KZ, Kyriakopoulos CE, Ntaidou TK, Falagas ME. Predictors of mortality in adult patients with ventilator-associated pneumonia: A meta-analysis. Shock. 2010;33:590–601.
    1. Inchai J, Pothirat C, Bumroongkit C, Limsukon A, Khositsakulchai W, Liwsrisakun C. Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care. 2015;3:9.
    1. Tseng CC, Fang WF, Huang KT, Chang PW, Tu ML, Shiang YP, et al. Risk factors for mortality in patients with nosocomial Stenotrophomonas maltophilia pneumonia. Infect Control Hosp Epidemiol. 2009;30:1193–202.
    1. Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J. Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia. Crit Care Med. 2007;35:146–54.
    1. Leu HS, Kaiser DL, Mori M, Woolson RF, Wenzel RP. Hospital-acquired pneumonia. Attributable mortality and morbidity. Am J Epidemiol. 1989;129:1258–67.
    1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
    1. Infectious Disease Association of Thailand. Thai Clinical Practice Guidelines for Management and Prevention of Adults with Hospital-Acquired and Ventilator-Associated Pneumonia. [Last accessed on 2014 Jan 17]. Available from: .
    1. Centres for Disease Control and Prevention. CDC/NHSN Surveillance Definitions for Specific Types of Infections. 2014. [Last accessed on 2014 Mar 11]. Available from: .
    1. Sopena N, Heras E, Casas I, Bechini J, Guasch I, Pedro-Botet ML, et al. Risk factors for hospital-acquired pneumonia outside the Intensive Care Unit: A case-control study. Am J Infect Control. 2014;42:38–42.
    1. Takano Y, Sakamoto O, Suga M, Muranaka H, Ando M. Prognostic factors of nosocomial pneumonia in general wards: A prospective multivariate analysis in Japan. Respir Med. 2002;96:18–23.
    1. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA. 2003;290:2588–98.
    1. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest. 2004;125:1791–9.
    1. Seligman R, Ramos-Lima LF, Oliveira Vdo A, Sanvicente C, Sartori J, Pacheco EF. Risk factors for infection with multidrug-resistant bacteria in non-ventilated patients with hospital-acquired pneumonia. J Bras Pneumol. 2013;39:339–48.
    1. Marechal H, Layios N, Damas P. The severity of ICU-acquired pneumonia. Curr Infect Dis Rep. 2013;15:380–4.
    1. Bekaert M, Timsit JF, Vansteelandt S, Depuydt P, Vésin A, Garrouste-Orgeas M, et al. Attributable mortality of ventilator-associated pneumonia: A reappraisal using causal analysis. Am J Respir Crit Care Med. 2011;184:1133–9.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する